Medical Condition News

RSS

Neuraltus reports positive results from NP001 Phase 1 study for ALS

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1 clinical study of NP001 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease).

30 Nov 2010

Intellikine and MMRC commence INK128 Phase I trial in multiple myeloma

Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a phase I trial of INK128, a novel, orally-available small molecule kinase inhibitor of the TORC1 and TORC2 complexes, in patients with multiple myeloma.

30 Nov 2010

Kenneth Rainin announces 2011 Innovator Awards Program for Inflammatory Bowel Disease

The Kenneth Rainin Foundation announced today its 2011 Innovator Awards Program for Inflammatory Bowel Disease. The Program, now in its second year, is designed to accelerate the pace of discovery in IBD research.

30 Nov 2010

Zogenix completes enrollment in ZX002 Phase 3 study for moderate to severe pain

Zogenix, Inc. today announced completion of enrollment in its open-label Phase 3 safety study (Study 802) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.

30 Nov 2010

Cyrenaic announces results of CYR-101 Phase IIa clinical trial for schizophrenia

Cyrenaic Pharmaceuticals Inc. a private drug development company focused on the treatment of CNS disorders, today announced Phase IIa clinical results for CYR-101, its novel investigational drug for the treatment of schizophrenia. The results from the study showed that the drug alleviated the symptoms of the disease, including the negative and cognitive symptoms.

30 Nov 2010

Spinal Modulation's Dorsal Root Ganglion Stimulation Pilot Clinical Trial results to be presented at 14th NANS

SPINAL MODULATION, Inc., a privately held medical device company focused on developing devices to treat chronic pain, today announced that the results of its prospective, multicenter Dorsal Root Ganglion (DRG) Stimulation Clinical Trial will be presented by David Caraway, MD, PhD, Timothy Deer, MD and Robert Levy, MD, PhD at the 14th Annual North American Neuromodulation Society (NANS) meeting.

30 Nov 2010

May Institute, Borders partner to raise funds for critical services during Benefit Days

May Institute, an award-winning national nonprofit serving children and adults with autism and other special needs, and Borders, a leading specialty retailer of books as well as other educational and entertainment items, are partnering this holiday season to raise funds for critical services during May Institute's Benefit Days at Borders, December 3-5, 2010. Visit May Institute's website to download a voucher with the promotional code for this special fundraising event.

30 Nov 2010

Group drumming can improve social, emotional behavior in low-income children: NAMM Foundation

The NAMM Foundation today announced the findings of a recent study that shows how group drumming can improve social and emotional behavior in low-income children.

30 Nov 2010

Super-sized World conference to address national health crisis of obesity

A conference at the New York Academy of Sciences on December 9 will convene leading obesity researchers to explore the latest science and policy initiatives addressing the global and national health crisis of obesity.

30 Nov 2010

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals, Inc. today announced positive top-line results from the Phase 3 short-term efficacy study component of its Phase 3 registration program of Zerenex (ferric citrate), the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

30 Nov 2010

University Hospitals receives $42 million for cancer care

Jane and Lee Seidman have donated $42 million to University Hospitals (UH) the largest gift in the Cleveland-based health system's history. In recognition of this unprecedented generosity, UH is naming the "Jane and Lee Seidman Cancer Center" in their honor.

30 Nov 2010

Interventional Radiology physician utilizes SUPERA VERITAS system to treat biliary stricture

IDEV Technologies, Incorporated, an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced the first procedure in the United States utilizing the SUPERA VERITAS Transhepatic Biliary System, which was recently cleared to market by the U.S. Food and Drug Administration.

30 Nov 2010

ImmunoGen initiates IMGN901 Phase I/II clinical trial in SCLC patients

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the initiation of a randomized Phase I/II clinical trial to evaluate its proprietary product candidate, IMGN901 (lorvotuzumab mertansine), for first-line treatment of small-cell lung cancer (SCLC) in patients with extensive disease.

30 Nov 2010

Cytheris' combinational therapy demonstrates possible therapeutic strategy for PML

Cytheris SA, a clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the publication of a case study report based on successful treatment of Progressive Multifocal Leukoencephalopathy (PML) with combination therapy consisting of two investigational agents, Cytheris' recombinant human interleukin-7 (CYT107) and CMX001, an investigational, oral broad-spectrum antiviral drug (Chimerix, Research Triangle Park, NC) in the Journal of Antimicrobial Chemotherapy.

30 Nov 2010

BioTrends releases annual syndicated publication of CKD-ND patient charts

BioTrends Research Group, Inc. released ChartTrends: Bone and Mineral Metabolism in Chronic Kidney Disease Non-Dialysis (CKD-ND), an annual syndicated publication based on patient and laboratory data collected from over 1,000 U.S.

30 Nov 2010

First-ever selective irreversible inhibition of viral protease using targeted covalent drug

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the first-ever selective irreversible inhibition of a viral protease using a targeted covalent drug.

30 Nov 2010

ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting

ARIAD Pharmaceuticals, Inc. today announced that updated clinical data from a fully enrolled Phase 1 trial of its investigational, pan-BCR-ABL inhibitor, ponatinib, will be presented at the 52nd Annual Meeting of the American Society of Hematology being held in Orlando, Florida, December 4-7, 2010.

30 Nov 2010

Genetic screening for Lynch syndrome as cost-effective as other cancer screening procedures

Myriad Genetics, Inc. today said results from a major health economics study in Cancer Prevention Research, a journal of the American Association for Cancer Research (AACR), found that screening for inherited gene mutations in the genes that cause a major colorectal cancer syndrome called Lynch Syndrome, is both medically and cost effective.

30 Nov 2010

New review from JASN highlights hazards of fructose

More and more people have become aware of the dangers of excessive fructose in diet. A new review on fructose in an upcoming issue of the Journal of the American Society of Nephrology (JASN) indicates just how dangerous this simple sugar may be.

30 Nov 2010

DATATRAK applauds Cosmo Pharmaceuticals for positive top-line results from budesonide MMX

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today publically congratulated its sponsor partner Cosmo Pharmaceuticals S.p.A. who last week announced positive top-line results from their second pivotal Phase III clinical study which was conducted in the EU utilizing DATATRAK's unified eClinical product suite and services team to evaluate the safety and efficacy of budesonide MMX for the induction of remission of mild or moderate ulcerative colitis.

30 Nov 2010

Medical Condition News

Neuraltus reports positive results from NP001 Phase 1 study for ALS

Intellikine and MMRC commence INK128 Phase I trial in multiple myeloma

Kenneth Rainin announces 2011 Innovator Awards Program for Inflammatory Bowel Disease

Zogenix completes enrollment in ZX002 Phase 3 study for moderate to severe pain

Cyrenaic announces results of CYR-101 Phase IIa clinical trial for schizophrenia

Spinal Modulation's Dorsal Root Ganglion Stimulation Pilot Clinical Trial results to be presented at 14th NANS

May Institute, Borders partner to raise funds for critical services during Benefit Days

Group drumming can improve social, emotional behavior in low-income children: NAMM Foundation

Super-sized World conference to address national health crisis of obesity

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

University Hospitals receives $42 million for cancer care

Interventional Radiology physician utilizes SUPERA VERITAS system to treat biliary stricture

ImmunoGen initiates IMGN901 Phase I/II clinical trial in SCLC patients

Cytheris' combinational therapy demonstrates possible therapeutic strategy for PML

BioTrends releases annual syndicated publication of CKD-ND patient charts

First-ever selective irreversible inhibition of viral protease using targeted covalent drug

ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting

Genetic screening for Lynch syndrome as cost-effective as other cancer screening procedures

New review from JASN highlights hazards of fructose

DATATRAK applauds Cosmo Pharmaceuticals for positive top-line results from budesonide MMX

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Latest News